JP2020534284A - ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法 - Google Patents

ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法 Download PDF

Info

Publication number
JP2020534284A
JP2020534284A JP2020515680A JP2020515680A JP2020534284A JP 2020534284 A JP2020534284 A JP 2020534284A JP 2020515680 A JP2020515680 A JP 2020515680A JP 2020515680 A JP2020515680 A JP 2020515680A JP 2020534284 A JP2020534284 A JP 2020534284A
Authority
JP
Japan
Prior art keywords
rsv
protein
rvsv
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020515680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534284A5 (enExample
Inventor
ステファン ニーウィスク
ステファン ニーウィスク
バサバラージ ビンジャワダジ
バサバラージ ビンジャワダジ
ジェンロン リ
ジェンロン リ
マーク ピープルズ
マーク ピープルズ
Original Assignee
オハイオ ステート イノベーション ファウンデーション
オハイオ ステート イノベーション ファウンデーション
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オハイオ ステート イノベーション ファウンデーション, オハイオ ステート イノベーション ファウンデーション, リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル, リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル filed Critical オハイオ ステート イノベーション ファウンデーション
Publication of JP2020534284A publication Critical patent/JP2020534284A/ja
Publication of JP2020534284A5 publication Critical patent/JP2020534284A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020515680A 2017-09-15 2018-09-14 ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法 Pending JP2020534284A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762559167P 2017-09-15 2017-09-15
US62/559,167 2017-09-15
PCT/US2018/051054 WO2019055768A1 (en) 2017-09-15 2018-09-14 VACCINES AND METHODS OF MAKING AND USING VACCINES FOR THE PREVENTION OF SYNCYTIAL RESPIRATORY VIRUS (RSV) INFECTIONS

Publications (2)

Publication Number Publication Date
JP2020534284A true JP2020534284A (ja) 2020-11-26
JP2020534284A5 JP2020534284A5 (enExample) 2021-10-21

Family

ID=65723867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020515680A Pending JP2020534284A (ja) 2017-09-15 2018-09-14 ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法

Country Status (8)

Country Link
US (1) US20200276297A1 (enExample)
EP (1) EP3681523A4 (enExample)
JP (1) JP2020534284A (enExample)
KR (1) KR20200096904A (enExample)
CN (1) CN111344008A (enExample)
AU (1) AU2018331467A1 (enExample)
CA (1) CA3075990A1 (enExample)
WO (1) WO2019055768A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240113662A (ko) * 2023-01-13 2024-07-23 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946446A1 (en) * 2019-04-02 2022-02-09 Sanofi Antigenic multimeric respiratory syncytial virus polypeptides
CN112226450B (zh) * 2020-08-25 2022-10-14 北京交通大学 一种共表达呼吸道合胞病毒融合前蛋白和黏附糖蛋白的复制缺陷型腺病毒载体疫苗
US20250127872A1 (en) * 2021-09-29 2025-04-24 Sk Bioscience Co., Ltd. Recombinant live attenuated rsv vaccine strain and production method therefor
CN118930654A (zh) * 2023-05-12 2024-11-12 中国科学院微生物研究所 一种呼吸道合胞病毒抗原制备方法和应用
CN117720628A (zh) * 2023-10-12 2024-03-19 中国科学院微生物研究所 一种呼吸道合胞病毒二价抗原制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247621A1 (en) * 2006-11-30 2010-09-30 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
JP2011507514A (ja) * 2007-12-20 2011-03-10 ワイス・エルエルシー Ｇタンパク質を発現する安定な細胞系を用いた、繁殖欠損水疱性口内炎ウイルスベクターをパッケージングする方法
JP2017523139A (ja) * 2014-06-13 2017-08-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1224462A (zh) * 1996-07-15 1999-07-28 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
BR0011159A (pt) * 1999-04-13 2002-07-23 Government Of The Us Dept Of H Método para produzir vacinas de vìrus rna de fita negativa atenuado a partir de sequências de nucleotìdeos clonados
AU2001264824A1 (en) * 2000-06-01 2001-12-11 St. Jude Children's Research Hospital Vaccine and gene therapy vector and methods of use thereof
AU2002327755A1 (en) * 2001-09-28 2003-04-14 Rush-Presbyterian-St. Luke's Medical Center Paramyxoviruses as gene transfer vectors to lung cells
CA2477235A1 (en) * 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
DE60330966D1 (de) * 2002-07-26 2010-03-04 Canada Natural Resources Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber
KR100999316B1 (ko) * 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
ATE555208T1 (de) * 2003-06-13 2012-05-15 Apath Llc Replikon eines negativsträngigen rna-virus
US8287878B2 (en) * 2004-04-09 2012-10-16 Wyeth Llc Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
WO2009025770A2 (en) * 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
RU2011122615A (ru) * 2008-11-05 2012-12-20 Мерк Шарп Энд Домэ Корп. Живой аттенуированный респираторно-синцитиальный вирус
KR102416194B1 (ko) * 2014-03-01 2022-07-04 프로펙츄스 바이오사이언스, 인크. 재조합 이스파한 바이러스 벡터

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247621A1 (en) * 2006-11-30 2010-09-30 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
JP2011507514A (ja) * 2007-12-20 2011-03-10 ワイス・エルエルシー Ｇタンパク質を発現する安定な細胞系を用いた、繁殖欠損水疱性口内炎ウイルスベクターをパッケージングする方法
JP2017523139A (ja) * 2014-06-13 2017-08-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGY LETTERS, vol. 150, JPN6022030719, 2013, pages 134 - 144, ISSN: 0005012020 *
JOURNAL OF VIROLOGY, vol. 82, JPN6022030722, 2008, pages 12191 - 12204, ISSN: 0005012021 *
JOURNAL OF VIROLOGY, vol. 88, JPN6022030718, 2014, pages 5122 - 5137, ISSN: 0005012022 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240113662A (ko) * 2023-01-13 2024-07-23 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법
KR102806300B1 (ko) 2023-01-13 2025-05-14 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법

Also Published As

Publication number Publication date
WO2019055768A1 (en) 2019-03-21
KR20200096904A (ko) 2020-08-14
CA3075990A1 (en) 2019-03-21
EP3681523A1 (en) 2020-07-22
AU2018331467A1 (en) 2020-04-30
US20200276297A1 (en) 2020-09-03
EP3681523A4 (en) 2021-12-29
CN111344008A (zh) 2020-06-26

Similar Documents

Publication Publication Date Title
JP2020534284A (ja) ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法
US11975067B2 (en) Coronavirus disease (COVID-19) vaccine
US9987353B2 (en) Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
JP2019510488A (ja) 抗腫瘍免疫を誘導するための、腫瘍関連抗原の複数のエピトープを発現するウイルスベクター
WO2022110099A1 (en) Coronavirus vaccines and uses thereof
EP2961846A1 (en) Crimean-congo haemorrhagic fever virus antigenic composition
US20100068226A1 (en) Polynucleotides and Uses Thereof
US20240115693A1 (en) Sars-cov-2 antigen nanoparticles and uses there of
US20210052718A1 (en) Respiratory syncytial virus (rsv) vaccines
WO2023064993A1 (en) Chimeric betacoronavirus spike polypeptides
EP4210741A1 (en) Vaccine for viral pathogens
ES2648337T3 (es) Uso del PACAP como adyuvante molecular para vacunas
Nath et al. A pervasive review on new advancements of nano vaccines on Covid-19 pandemic
JP2003528614A (ja) 肝炎ウイルスのｏｒｆ２のｎ末端領域に由来するプロセシング成分および抗原性ポリペプチドをコードする核酸構築物
US20230364220A1 (en) SAR-COV-2 DNA Vaccine and Method of Administering Thereof
US20230295244A1 (en) Compositions and methods for treating and preventing coronaviruses
HK40029686A (en) Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
CN117599160A (zh) 狂犬病疫苗免疫原组合物
JP2023024409A (ja) Ｓｎａｒｅを活用した核酸構築物
TW202406929A (zh) 多表位構築體
EP4282429A1 (en) Multivalent covid-19 vaccines based on adenoviral vectors
CN117120617A (zh) 新型核酸分子
Allahverdiyev et al. Overview on under development of vaccine candidates against SARS-CoV-2
JPWO2005090576A1 (ja) 百日咳感染症予防用ｄｎａ構築物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230314